Labcorp (NYSE:LH) has expanded its collaboration with PathAI to integrate PathAI’s FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs. This move aims to scale digital pathology nationwide, incorporate AI insights into routine care, and support precision medicine products. The partnership builds on a 2019 investment and follows recent positive Q4 2025 earnings for Labcorp, despite a revenue shortfall.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Labcorp expands PathAI collaboration for digital pathology rollout
Labcorp (NYSE:LH) has expanded its collaboration with PathAI to integrate PathAI’s FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs. This move aims to scale digital pathology nationwide, incorporate AI insights into routine care, and support precision medicine products. The partnership builds on a 2019 investment and follows recent positive Q4 2025 earnings for Labcorp, despite a revenue shortfall.